Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease.

Milica Stojkovic Lalosevic,Djordje Culafic,Marko Aleksic,Stefan Stojkovic,Mihailo Stjepanovic,Ljubisa Toncev,Milos Stulic,Jovan Lalosevic,Tamara Milovanovic,Aleksandra Pavlovic Markovic,Mirjana Stojkovic,Marija Stojanovic,Branislav Oluic,Sanja Stankovic,Stanimir Kiurski,Sanja Dragasevic,Ivana Jovicic,Roberta Rizzo

doi:10.1155/2020/8523205

Milica Stojkovic Lalosevic, Djordje Culafic + Show 16 more

Open Access

https://doi.org/10.1155/2020/8523205

Copy DOI

Journal: Disease markers	Publication Date: Nov 28, 2020
Citations: 10	License type: CC BY 4.0

Affiliation: Centar za Promociju Nauke, University of Belgrade

Abstract

Results There was a high statistically significant difference between IBD patients and controls in levels of hepcidin (P < 0.01). Namely, serum hepcidin levels were significantly higher in the control group. There was no statistically significant correlation of serum hepcidin with CRP, Mayo score, or CDAI, respectively (P > 0.05). However, we have found a statistically significant negative correlation of sTfR and TIBC with hepcidin (P < 0.01). Conclusion Results of our study suggest that hepcidin is a reliable marker of IDA in patients with IBD, and it could be used in routine clinical practice when determining adequate therapy in these patients.

Highlights

Anemia is one of the most common complications of inflammatory bowel disease (IBD), with the prevalence up to 70% at the time of diagnosis establishment [1, 2]
Results of our study suggest that hepcidin is a reliable marker of iron deficiency anemia (IDA) in patients with IBD, and it could be used in routine clinical practice when determining adequate therapy in these patients
When we analyzed only IBD patients, we found no statistically significant correlation between values of soluble transferrin receptor (sTfR) and disease activity presented by Mayo score, Crohn’s disease activity index (CDAI), endoscopic, and histopathological findings (P < 0:01)

Summary

Introduction

Anemia is one of the most common complications of inflammatory bowel disease (IBD), with the prevalence up to 70% at the time of diagnosis establishment [1, 2]. Treatment is determined by the etiology, and in the majority of the patients with IBD, anemia may be due to iron deficiency (IDA) or inflammation [1]. Differentiating these two most common etiologies represents a clinical challenge. There was no statistically significant correlation of serum hepcidin with CRP, Mayo score, or CDAI, respectively (P > 0:05). Results of our study suggest that hepcidin is a reliable marker of IDA in patients with IBD, and it could be used in routine clinical practice when determining adequate therapy in these patients

Objectives

Methods

Results

Conclusion